119 related articles for article (PubMed ID: 21756079)
1. Pioglitazone reduces central obesity in polycystic ovary syndrome women.
Asadipooya K; Kalantar-Hormozi M; Nabipour I
Gynecol Endocrinol; 2012 Jan; 28(1):16-9. PubMed ID: 21756079
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
3. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
4. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome.
Stabile G; Borrielli I; Artenisio AC; Bruno LM; Benvenga S; Giunta L; La Marca A; Volpe A; Pizzo A
J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):177-82. PubMed ID: 24814528
[TBL] [Abstract][Full Text] [Related]
5. Estimation of truncal adiposity using waist circumference or the sum of trunk skinfolds: a pilot study for insulin resistance screening in hirsute patients with or without polycystic ovary syndrome.
Toscani M; Migliavacca R; Sisson de Castro JA; Spritzer PM
Metabolism; 2007 Jul; 56(7):992-7. PubMed ID: 17570263
[TBL] [Abstract][Full Text] [Related]
6. Anthropometric indices of central obesity how discriminators of metabolic syndrome in Brazilian women with polycystic ovary syndrome.
Costa EC; Sá JC; Soares EM; Lemos TM; Maranhão TM; Azevedo GD
Gynecol Endocrinol; 2012 Jan; 28(1):12-5. PubMed ID: 21958393
[TBL] [Abstract][Full Text] [Related]
7. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
[TBL] [Abstract][Full Text] [Related]
8. Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome.
Narsing Rao L; Jacob JJ; Paul TV; Rajarathinam S; Thomas N; Seshadri MS
J Pediatr Adolesc Gynecol; 2009 Apr; 22(2):91-5. PubMed ID: 19345914
[TBL] [Abstract][Full Text] [Related]
9. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference.
Bruno RV; de Avila MA; Neves FB; Nardi AE; Crespo CM; Sobrinho AT
Fertil Steril; 2007 Aug; 88(2):510-2. PubMed ID: 17433315
[TBL] [Abstract][Full Text] [Related]
11. [Metformin treatment with or without life style changes in patients with polycystic ovary syndrome].
Petrányi G; Zaoura-Petrányi M
Orv Hetil; 2011 Apr; 152(16):628-32. PubMed ID: 21454179
[TBL] [Abstract][Full Text] [Related]
12. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.
Romualdi D; Guido M; Ciampelli M; Giuliani M; Leoni F; Perri C; Lanzone A
Hum Reprod; 2003 Jun; 18(6):1210-8. PubMed ID: 12773448
[TBL] [Abstract][Full Text] [Related]
13. Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome.
Tiwari N; Pasrija S; Jain S
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():149-154. PubMed ID: 30690191
[TBL] [Abstract][Full Text] [Related]
14. High serum dehydroepiandrosterone sulfate is associated with phenotypic acne and a reduced risk of abdominal obesity in women with polycystic ovary syndrome.
Chen MJ; Chen CD; Yang JH; Chen CL; Ho HN; Yang WS; Yang YS
Hum Reprod; 2011 Jan; 26(1):227-34. PubMed ID: 21088016
[TBL] [Abstract][Full Text] [Related]
15. Optimal waist circumference for prediction of metabolic syndrome in young Korean women with polycystic ovary syndrome.
Oh JY; Sung YA; Lee HJ; Oh JY; Chung HW; Park H
Obesity (Silver Spring); 2010 Mar; 18(3):593-7. PubMed ID: 19763092
[TBL] [Abstract][Full Text] [Related]
16. Thiazolinedione treatment in PCOS--an update.
Glintborg D; Andersen M
Gynecol Endocrinol; 2010 Nov; 26(11):791-803. PubMed ID: 20528570
[TBL] [Abstract][Full Text] [Related]
17. [Use of yasmin in the treatment of women with polycystic ovary syndrome].
Pekhlivanov B; Mitkov M; Ivancheva Kh; Amaliev I
Akush Ginekol (Sofiia); 2006; 45(3):25-9. PubMed ID: 16889184
[TBL] [Abstract][Full Text] [Related]
18. [Treatment experience with metformin in polycystic ovary syndrome].
Petrányi G
Orv Hetil; 2005 May; 146(21):1151-5. PubMed ID: 15991679
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones for treatment of polycystic ovary syndrome.
Stout DL; Fugate SE
Pharmacotherapy; 2005 Feb; 25(2):244-52. PubMed ID: 15767238
[TBL] [Abstract][Full Text] [Related]
20. Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Ibáñez L; Del Río L; Díaz M; Sebastiani G; Pozo ÓJ; López-Bermejo A; de Zegher F
J Adolesc Health; 2017 Oct; 61(4):446-453. PubMed ID: 28712591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
